Janus kinase inhibitors in pulmonary and extra-pulmonary sarcoidosis: A case series and a systematic review of the literature
Maxime Quaggetto, Thouraya Ben Salem, Julien Haroche, Julien Campagne, Quentin Moyon, Raphael Lhote, Zahir Amoura, Fleur Cohen Aubart · 2025
Read Janus kinase inhibitors in pulmonary and extra-pulmonary sarcoidosis: A case series and a systematic review of the literature by Maxime Quaggetto, Thouraya Ben Salem, Julien Haroche, Julien Campagne, Quentin Moyon, Raphael Lhote, Zahir Amoura, Fleur Cohen Aubart (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12815289.txt.
Description
Maxime Quaggetto and co-authors report a 2025 study of a drug class for sarcoidosis, a swelling disease that most often hits the lungs and skin. Steroids are the usual care, but some patients stay ill or need a lower dose. The team adds four new cases and reviews all past reports they could find.
In total they cover forty-nine patients, most treated with one drug in this class twice a day. After about eight months, nearly half had a full response and nearly half a partial one. Side effects were few in the reports. Many patients cut or stopped steroids. The authors call the results hopeful but say planned trials are still needed.
Catalog record
| CREATOR | Maxime Quaggetto, Thouraya Ben Salem, Julien Haroche, Julien Campagne, Quentin Moyon, Raphael Lhote, Zahir Amoura, Fleur Cohen Aubart |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |